Amgen’s Xgeva Gains FDA Nod For Use In Rare Bone Tumor
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval of denosumab for giant cell tumor of the bone comes more than a year after Amgen’s failed bid to add a more commercially significant indication for prevention of bone metastases in patients with castrate-resistant prostate cancer.